News Daily News Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI Michael O'Riordan April 22, 2025
News Daily News Topline Data Point to Promise for VERVE-102 Gene-Editing Therapy Caitlin E. Cox April 14, 2025
News Conference News ACC 2025 ALPACA: Injectable siRNA Agent Safe and Effective for Lowering Lp(a) L.A. McKeown April 10, 2025
News Conference News ACC 2025 Nurses Can Be Pivotal in Post-ACS Secondary Prevention: ALLEPRE Caitlin E. Cox April 02, 2025
News Daily News Cannabis Use Again Tied to Increased CVD Risk in Young People L.A. McKeown March 19, 2025
News Daily News Newer Weight-Loss Drugs Not Cost-effective at Current Prices Michael O'Riordan March 18, 2025
News Daily News Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD Michael O'Riordan March 06, 2025
News Daily News Genetic Risk Score for Endothelial Cell Dysfunction May Help Hone ASCVD Care Michael O'Riordan February 27, 2025
News Daily News Olpasiran Cuts Lp(a) but Not Inflammatory Markers: OCEAN(a)-DOSE Yael L. Maxwell February 14, 2025
News Daily News Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab Michael O'Riordan February 05, 2025
News Daily News Higher Lp(a) Indicates Greater Chance of Stenosis on CCTA in Patients With Chest Pain Yael L. Maxwell January 13, 2025
News Daily News Young Men Who Take Steroids Have Impaired Coronary Flow, Even After Quitting Caitlin E. Cox December 17, 2024
News Daily News Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE Yael L. Maxwell December 13, 2024
News Opinion Editor's Corner TCTMD’s Top 10 Most Popular Stories for November 2024 Shelley Wood December 03, 2024
News Conference News AHA 2024 ZODIAC: Decision-Support Tool Doesn’t Sway Lipid-Lowering Treatments in ACS Michael O'Riordan November 21, 2024
News Conference News AHA 2024 Clues to Evolocumab Response Exist in Patients’ Genes: YELLOW III Caitlin E. Cox November 21, 2024
News Conference News AHA 2024 Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360 Michael O'Riordan November 18, 2024